Second pivotal Phase III trial of cobimetinib plus atezolizumab versus a PD-1 inhibitor in patients with previously untreated BRAF wild-type advanced melanoma
Phase of Trial: Phase III
Latest Information Update: 20 Jul 2017
At a glance
- Drugs Atezolizumab (Primary) ; Cobimetinib (Primary) ; Pembrolizumab
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- Acronyms IMspire170
- Sponsors Genentech
- 20 Jul 2017 This trial is expected to begin in the third quarter of 2017, according to an Exelixis media release.
- 01 May 2017 According to an Exelixis media release, this trial is expected to enroll its first patient in the second quarter of 2017.
- 21 Nov 2016 New trial record